Epizyme

Epizyme

Biotechnology, 400 Technology Square, Cambridge, , 2139, Massachusetts, United States, 201-500 Employees

epizyme.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: 61********

Who is EPIZYME

On August 12, 2022, Epizyme was acquired by Ipsen, expanding Ipsen’s oncology portfolio. Epizyme now operates as an Ipsen company with a shared goal of delivering innovative treatment opt...

Read More

map
  • 400 Technology Square, Cambridge, Massachusetts, 2139, United States Headquarters: 400 Technology Square, Cambridge, Massachusetts, 2139, United States
  • 2007 Date Founded: 2007
  • 201-500 Employees: 201-500
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from EPIZYME

Epizyme Org Chart and Mapping

Employees

Fei Wang

Senior Research Associate

Dina Feith

Associate Director of Analytical Development and Quality Control

Nick Orlando

Oncology Account Manager

Indu Subramanian

Senior Research Associate

Karen Hummel

Executive Director, National Health Systems, Medical Affairs

Jose G

Senior Technical Analyst

Cynthia Villarimo

Senior Director Medical Science Liaison

Goutham Maddi

Senior Clinical Data Manager

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Epizyme

Answer: Epizyme's headquarters are located at 400 Technology Square, Cambridge, , 2139, Massachusetts, United States

Answer: Epizyme's phone number is 61********

Answer: Epizyme's official website is https://epizyme.com

Answer: Epizyme's revenue is $50 Million to $100 Million

Answer: Epizyme's SIC: 2836

Answer: Epizyme's NAICS: 325414

Answer: Epizyme has 201-500 employees

Answer: Epizyme is in Biotechnology

Answer: Epizyme contact info: Phone number: 61******** Website: https://epizyme.com

Answer: On August 12, 2022, Epizyme was acquired by Ipsen, expanding Ipsen’s oncology portfolio. Epizyme now operates as an Ipsen company with a shared goal of delivering innovative treatment options to underserved patients. Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. It develops and commercializes innovative medicines in three key therapeutic areas - Oncology, Neuroscience and Rare Disease. Its commitment to oncology is exemplified through its growing portfolio of key therapies for prostate cancer, neuroendocrine tumors, renal cell carcinoma and pancreatic cancer. Neuroscience is advancing at an unprecedented rate and Ipsen is at the forefront of this transformation.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access